Randomized, double-blind, placebo-controlled, phase iii chemoprevention trial of selenium supplementation in patients with resected stage i non-small-cell lung cancer: ECOG 5597

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages 4179-4187

  Karp, Daniel D ^a   Lee, Sandra J ^c   Keller, Steven M ^d   Wright, Gail Shaw ^e   Aisner, Seena ^f   Belinsky, Steven Alan ^g   Johnson, David H ^b   Johnston, Michael R ^p,q   Goodman, Gary ^h,i   Clamon, Gerald ^j   Okawara, Gordon ^r   Marks, Randolph ^k   Frechette, Eric ^s   McCaskill Stevens, Worta ^l   Lippman, Scott M ^m   Ruckdeschel, John ⁿ   Khuri, Fadlo R ^o  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e Florida Cancer Specialists   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^g LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^h Swedish Medical Center Cancer Institute   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j UNIVERSITY OF IOWA   (United States)

^k MAYO CLINIC   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁿ INTERMOUNTAIN HEALTHCARE   (United States)

^o EMORY UNIVERSITY   (United States)

^p DALHOUSIE UNIVERSITY   (Canada)

^q Queen's Cancer Research Institute   (Canada)

^r MCMASTER UNIVERSITY   (Canada)

^s LAVAL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; CREATININE; HEMOGLOBIN; PLACEBO; SELENIUM;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; AMNESIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER INCIDENCE; CHEMOPROPHYLAXIS; COLITIS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DERMATITIS; DESQUAMATION; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRY SKIN; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EDEMA; EMBOLISM; ENDOCRINE DISEASE; EPIPHORA; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; FLATULENCE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; INSOMNIA; LEUKOCYTE; LIBIDO; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MOTOR NEUROPATHY; MYALGIA; MYOSITIS; NAIL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUTROPHIL; OVERALL SURVIVAL; PERSONALITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND DISEASE; SECOND CANCER; SENSORY NEUROPATHY; SKIN BRUISING; SKIN CANCER; SKIN PIGMENTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOSIS; TREATMENT DURATION; URINARY FREQUENCY; URINARY URGENCY; URTICARIA; VERTIGO; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; KAPLAN MEIER METHOD; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; LUNG NEOPLASMS; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOPREVENTION; CONSTIPATION; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; SELENIUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892947736     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.2173     Document Type: Article

References (35)

1. Stewart SL, Cardinez CJ, Richardson LC, et al: Surveillance for cancers associated with tobacco use: United States, 1999-2004. MMWR Surveill Summ 57:1-33, 2008
2. Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862, 1997 (Pubitemid 27268450)
3. Suda K, Tomizawa K, Yatabe Y, et al: Lung cancers unrelated to smoking: Characterized by single oncogene addiction? Int J Clin Oncol 16:294- 305, 2011
4. Tammemagi CM, Pinsky PF, Caporaso NE, et al: Lung cancer risk prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 103:1058-1068, 2011
5. Hennekens CH, Buring JE, Manson JE, et al: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996 (Pubitemid 26137972)
6. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers: The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035, 1994
7. Lee JS, Lippman SM, Benner SE, et al: Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12:937-945, 1994 (Pubitemid 24145320)
8. Kurie JM, Lee JS, Khuri FR, et al: N-(4- hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6:2973-2979, 2000 (Pubitemid 30637717)
9. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996 (Pubitemid 26137973)
10. Heimburger DC, Alexander CB, Birch R, et al: Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12: Report of a preliminary randomized, double-blind intervention trial. JAMA 259:1525-1530, 1988 (Pubitemid 18062072)
11. Rothwell PM, Fowkes FG, Belch JF, et al: Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377:31-41, 2011
12. Mao JT, Roth MD, Fishbein MC, et al: Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4:984-993, 2011
13. Kim ES, Hong WK, Lee JJ, et al: Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 3:148-159, 2010
14. Keith RL, Blatchford PJ, Kittelson J, et al: Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 4:793-802, 2011
15. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990 (Pubitemid 20303877)
16. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222, 1993 (Pubitemid 23199122)
17. van Zandwijk N, Dalesio O, Pastorino U, et al: EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer: For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92:977-986, 2000
18. Lippman SM, Lee JJ, Karp DD, et al: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605-618, 2001
19. Khuri FR, Lee JJ, Lippman SM, et al: Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98:441-450, 2006
20. Blot WJ, Li JY, Taylor PR, et al: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993 (Pubitemid 23269183)
21. Mark SD, Qiao YL, Dawsey SM, et al: Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 92:1753-1763, 2000
22. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial - Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996 (Pubitemid 26427723)
23. Reid ME, Duffield-Lillico AJ, Garland L, et al: Selenium supplementation and lung cancer incidence: An update of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11:1285-1291, 2002 (Pubitemid 35340362)
24. Fleet JC: Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev 55:277- 279, 1997 (Pubitemid 27394075)
25. Belinsky SA, Klinge DM, Dekker JD, et al: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11:6505-6511, 2005 (Pubitemid 41338988)
26. Johnson BE: Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90:1335-1345, 1998
27. Duffield-Lillico AJ, Slate EH, Reid ME, et al: Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95:1477-1481, 2003 (Pubitemid 37279333)
28. Stranges S, Marshall JR, Natarajan R, et al: Effects of long-term selenium supplementation on the incidence of type 2 diabetes: A randomized trial. Ann Intern Med 147:217-223, 2007 (Pubitemid 351664577)
29. Lippman SM, Klein EA, Goodman PJ, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301:39- 51, 2009
30. Herbst RS, Lippman SM: Molecular signatures of lung cancer: Toward personalized therapy. N Engl J Med 356:76-78, 2007 (Pubitemid 46041757)
31. Ramalingam SS, Owonikoko TK, Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61:91-112, 2011
32. Govindan R, Ding L, Griffith M, et al: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134, 2012
33. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
34. Memmott RM, Mercado JR, Maier CR, et al: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 3:1066- 1076, 2010
35. Aberle DR, Adams AM, Berg CD, et al: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409, 2011